NEW YORK (GenomeWeb) – With its initial foray into the use of next-generation sequencing technology, Kura Oncology aims to resuscitate a drug that the US Food and Drug Administration deemed not approvable a decade ago. 

Last week, Kura announced that it had licensed from Johnson & Johnson's Janssen Pharmaceutica the exclusive rights to develop and commercialize the protein farnesyltransferase inhibitor tipifarnib (Zarnestra) in the field of oncology. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.